Mono-Femara 2.5mg/tab 50 Tabletten by Beligas Pharmaceuticals

Usage

1. Determine cycle clearance window: allow 2–5 days post-cycle for short esters (propionate) or 10–14 days for long esters (enanthate/decanoate) before introducing Mono-Femara.
2. Begin at 1.25 mg every other day — split a scored 2.5 mg tablet — to establish a conservative baseline estrogen-control dose without risking over-suppression at PCT start.
3. Take each tablet orally with a glass of water, with or without food; letrozole demonstrates consistent bioavailability under both fed and fasted conditions.
4. Schedule bloodwork at PCT week 2: test serum estradiol (E2), LH, FSH, and total testosterone to assess axis recovery trajectory and calibrate dose progression.
5. Taper the dose progressively across weeks 3–6 based on bloodwork results; do not maintain a high dose throughout PCT as chronically suppressed estradiol inhibits bone density, cardiovascular function, and mood stability.
6. Cease Mono-Femara only after a final blood panel confirms LH, FSH, and testosterone are within normal physiological ranges; document lot number and dosing log for personal medical records.

Warnings

Frequently asked questions

When should I start taking Letrozole in a post-cycle therapy protocol?

Letrozole PCT timing depends on the esters used during cycle. For short-ester compounds (e.g., propionate), PCT typically begins 2–3 days after the last injection; for long-ester compounds (e.g., enanthate or decanoate), a 10–14 day clearance window is standard before introducing Letrozole at 1.25–2.5 mg every other day to manage estrogen rebound during hormonal restoration.

Is Letrozole a good choice for post-cycle estrogen control compared to other aromatase inhibitors?

Letrozole is one of the most potent aromatase inhibitors available, capable of suppressing estradiol synthesis by up to 98% under study conditions — making it particularly suited to PCT phases where aromatisation risk is elevated. Unlike steroidal AIs, its non-covalent, reversible mechanism means aromatase function normalises after cessation, supporting a cleaner transition back to baseline hormonal function.

How long does post-cycle hormonal recovery typically take when using Letrozole?

Full HPG-axis recovery varies by cycle length, compound stack, and individual physiology, but most protocols run 4–6 weeks. Letrozole's role during this window is to reduce the estrogen-driven negative feedback on LH and FSH, accelerating gonadotropin recovery. Serum LH, FSH, and testosterone levels should be monitored via bloodwork at week 2 and week 4 to assess trajectory and guide tapering.

What is the advantage of the 2.5 mg tablet strength for dose adjustments during PCT?

The 2.5 mg tablet strength allows flexible dose titration — the standard oncological dose — while also permitting half-tablet splitting to achieve a practical 1.25 mg every-other-day starting dose commonly preferred in PCT settings. Lower starting doses reduce the risk of crashing estradiol too aggressively, which can impair libido and mood; Mono-Femara's scored tablet design supports this graduated approach.

How are Mono-Femara tablets packaged and how should they be stored?

Mono-Femara comes in a 50-tablet blister pack, providing a full multi-week PCT supply in a single purchase. Tablets should be stored below 25°C in a dry, light-protected environment to maintain letrozole stability across the pack's shelf life. The blister format protects individual tablets from humidity until point of use, preserving integrity for every dose throughout the protocol. (2) angle_used

Manufacturer

The release pathway for Mono-Femara at Beligas Pharmaceuticals begins with a question the company embedded in its standard operating procedures from the outset: can we verify it, or are we only claiming it? That question shapes how every Letrozole tablet exits the facility. Rather than relying on process consistency as a proxy for active-ingredient accuracy, Beligas assigns each production lot a mandatory analytical identity: HPLC quantification isolates the letrozole peak from tablet excipients, measures it against certified pharmacopoeial reference standards, and returns a lot-specific confirmed value — the number that appears on the release documentation and reflects what is physically present in every tablet. This is not an interpolated average across production runs; it is a discrete, chromatographically produced figure tied to a unique lot number. Alongside HPLC, the LAL (Limulus Amebocyte Lysate) endotoxin screening protocol is applied prior to distribution, ensuring that pharmaceutical-grade purity extends beyond active-ingredient concentration to include pyrogenic contamination absence. Beligas Pharmaceuticals built its catalogue identity around the principle that a release certificate is only as trustworthy as the analytical methodology that generated it — and that principle, established during the company's earliest years in the pharmaceutical-grade performance supplement sector, remains structurally unchanged across every product it brings to market.